paul f truex  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in paul f truex executive chairman of the board at anthera pharmaceuticals inc view full profile are you paul f truex claim your profile   sign up for equilar atlas and view paul f truexs full profile with equilar atlas you can identify corporate executives in paul f truexs network and community follow changes in paul f truexs employment and moneyinmotion connect with paul f truex through your network of contacts paul f truexs executive work history current executive chairman of the board anthera pharmaceuticals inc board member cymabay therapeutics past to view paul f truexs complete executive work history sign up now age      paul f truexs biography mr truex has served as executive chairman of the board since december  mr truex previously served as our director chief executive officer and president from our inception in september  until january  and as our director and chief executive officer from september  until january  he was responsible for negotiating our product licenses for both blisibimod our antibaff peptibody program from amgen inc and sollpuratm liprotamase a novel enzyme product from eli lilly and company prior to founding anthera mr truex served as a founder director president and chief executive officer of peninsula pharmaceuticals  read more mr truex has served as executive chairman of the board since december  mr truex previously served as our director chief executive officer and president from our inception in september  until january  and as our director and chief executive officer from september  until january  he was responsible for negotiating our product licenses for both blisibimod our antibaff peptibody program from amgen inc and sollpuratm liprotamase a novel enzyme product from eli lilly and company prior to founding anthera mr truex served as a founder director president and chief executive officer of peninsula pharmaceuticals inc peninsula from the commencement of its operations in october  during that time mr truex negotiated both of peninsulas product agreements with shionogi  co ltd doribax� doripenem and takeda chemical industries teflaro� ceftaroline peninsula was acquired by johnson and johnson for  million in an all cash transaction the remaining entity cerexa was subsequently acquired for  million in cash by forest laboratories prior to peninsula mr truex was vice president of commercial development for versicor inc acquired by pfizer from april  to september  where he directed early commercial efforts for versicors infectious disease portfolio and participated in versicors initial public offering from july  to april  mr truex worked at eli lilly and company eli lilly where he served in various marketing and sales roles during the launch of three different products for the primary care physician market actos� evista� and humalog � his business development experience included the lilly icos llc joint ventures two major product divestitures and numerous small research collaborations mr truex obtained his mba in marketing and finance from indiana university and a ba in economics from the university of waterloo mr truex is currently the chairman and a director of milestone pharmaceuticals inc cymabay therapeutics inc nasdaq cbay and lqt therapeutics he previously served on the board of directors of both trius therapeutics inc acquired by cubist pharmaceuticals inc in july  and protagonist therapeutics inc nasdaq ptgx the board of directors believes mr truex is suited to serve on our board due to his deep knowledge of the company gained from his previous position as president and chief executive officer as well as his substantial experience in the pharmaceutical industry source anthera pharmaceuticals inc on    sign up for equilar atlas and view paul f truexs full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like paul f truex more specifically youll be able to identify corporate executives in paul f truexs network and community follow changes in paul f truexs employment and moneyinmotion connect with paul f truex through your network of conections view full profile   search for over  executive profiles bio example paul f truex paul f truexs connections  sign up now to view paul f truexs  connections » michael f powell former board member ocera therapeutics inc william r shanahan senior vice president and chief medical officer anthera pharmaceuticals inc james i healy former board member ascendis pharma as theodore r schroeder former board member collegium pharmaceutical inc may liu senior vice president finance and administration and principal accounting officer anthera pharmaceuticals inc david e thompson board member anthera pharmaceuticals inc debra odink former advisor anthera pharmaceuticals inc stephen lau former vp corp  business dev anthera pharmaceuticals inc georgina kilfoil former senior vice president product development and clinical operations anthera pharmaceuticals inc chuck olson advisor anthera pharmaceuticals inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   paul f truex  executive chairman at anthera pharmaceuticals inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink paul f truex executive chairman at anthera pharmaceuticals inc overview in the news relationships paths education career history boards  committees investments public holdings transactions paul f truex executive chairman at anthera pharmaceuticals inc overview age  born  notable companies anthera pharmaceuticals inc peninsula pharmaceuticals inc board seats  number of relationships this person is connected to  people in the news see more pr newswire march   milestone pharmaceuticals announces appointment of joseph g oliveto as chief executive officer globenewswire february   anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results pr newswire december   technical reports on biotech equities  jazz pharma anthera pharma pronai therapeutics and avexis globenewswire march   cymabay reports fourth quarter and full year  financial results globenewswire march   cymabay announces the appointment of paul f truex and robert j weiland to its board of directors see full news coverage and complete stories with relsci professional create your news feed see more relationships see details john craig thompson president  chief executive officer at anthera pharmaceuticals inc philip sager chief medical advisor at milestone pharmaceuticals inc david e thompson former director of corporate new product planning  licensing at eli lilly  company philippe douville founder at milestone pharmaceuticals inc james i healy general partner  managing director at sofinnova ventures inc christopher s henney former interim chief executive officer at cascadian therapeutics inc steven engle chief executive officer at averigon consulting brian r mueller chief accounting officer senior vice president  controller at biomarin pharmaceutical inc eric w linsley chief financial officer  treasurer at envisia therapeutics inc sujal shah interim president  chief executive officer at cymabay therapeutics inc see  more listings with relsci professional start my free trial ➤ see  more paths to paul f truex paul f truex you connections via relationship science paul f truex sync your contacts to see how you can connect with paul f truex start my free trial ➤ see more educational background bachelor of arts degree in economics  university of waterloo university of waterloo is home to worldchanging research and inspired teaching at the hub of a growing network of global partnerships waterloo will shape the future by building bridges with industry and between disciplines institutions and communities graduate  indiana university indiana university is a major multicampus public research institution grounded in the liberal arts and sciences and a world leader in professional medical and technological education indiana university’s mission is to provide broad access to undergraduate graduate and continuing education for students throughout indiana the united states and the world as well as outstanding academic and cultural programs and student services indiana university seeks to create dynamic partnerships with the state and local communities in economic social and cultural development and to offer leadership in creative solutions for st century problems indiana university strives to achieve full diversity and to maintain friendly collegial and humane environments with a strong commitment to academic freedom mba in marketing  finance  indiana university  kelley school of business founded in  as the indiana university school of commerce and finance the kelley school has grown into one of the most respected business schools in the world the kelley school offers undergraduate mba master’s graduate certificates and doctoral degrees at iu’s bloomington and indianapolis campuses career history executive chairman   current anthera pharmaceuticals inc anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca executive officer current milestone pharmaceuticals inc milestone pharmaceuticals inc develops cardiovascular drugs it operates as a cardiovascular drug development company which develops small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases the firm’s product msp is a novel and potent shortacting calcium channel antagonist for the systemic treatment of psvt in phase  clinical studies the company was founded by philippe douville in  and is headquartered in saintlaurent canada president  chief executive officer    peninsula pharmaceuticals inc peninsula pharmaceuticals inc used to develop and commercialize antibiotics to treat life threatening infections the company used to develop optimal antiinfective therapies that offer improved efficacy dosing and safety characteristics over existing therapies it was founded in  the company was located in alameda ca vice president    vicuron pharmaceuticals inc vicuron pharmaceuticals inc develops pharmaceutical products it engages in discovering developing manufacturing and commercializing vital medicine for seriously ill patients the company offers anidulafungin drug which prevents cell wall formation and other infectious fungi it also offers antibiotic for the treatment of complicated skin and softtissue infections the company was founded by christopher t walsh in  and is located in king of prussia pa head of sales  marketing    eli lilly  company eli lilly  co engages in the discovery development manufacture and sale of pharmaceutical products it operates through the human pharmaceutical products and animal health segments the human pharmaceutical products segment includes the discovery development manufacturing marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas neuroscience endocrinology oncology cardiovascular and other the animal health segment operating through the elanco animal health division develops manufactures and markets products for both food and companion animals the animal health products include rumensin tylan posilac paylean and other products for livestock and poultry as well as trifexis comfortis and other products for companion animals the other pharmaceuticals products include antiinfectives primarily vancocin and ceclor and other miscellaneous pharmaceutical products and services its products are distributed through wholesalers that serve pharmacies physicians and other health care professionals and hospitals the company was founded by eli lilly on may  and is headquartered in indianapolis in observer president  chief executive officer prior eiger biopharmaceuticals inc eiger biopharmaceuticals inc is a clinicalstage company which engages in the research development and commercialization of biopharmaceutical products it focuses on product candidates for the treatment of orphan diseases such as sarasar pegylated interferon lambda exendin  and ubenimex the company was founded by david a cory on november   and is headquartered in palo alto ca boards  committees corporate boards ▾ member board of directors   current cymabay therapeutics inc cymabay therapeutics inc is a clinical stage company which engages in the research and development of biopharmaceutical products its candidates include mbx and arhalofenate mbx aims to treat lipid and liver diseases while arhalofenate intends to reduce gout flares and serum uric acid the company was founded on october   and is headquartered in newark ca chairman   current milestone pharmaceuticals inc milestone pharmaceuticals inc develops cardiovascular drugs it operates as a cardiovascular drug development company which develops small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases the firm’s product msp is a novel and potent shortacting calcium channel antagonist for the systemic treatment of psvt in phase  clinical studies the company was founded by philippe douville in  and is headquartered in saintlaurent canada executive chairman board of directors   current anthera pharmaceuticals inc anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca director current waterloo pharmaceuticals inc independent director    trius therapeutics inc trius therapeutics is a biopharmaceutical company focused on the discovery development and commercialization of innovative antibiotics for lifethreatening infections we have successfully completed our first phase  clinical trial for tedizolid phosphate tr formerly torezolid phosphate in absssi tedizolid is an iv and orally administered second generation oxazolidinone for the treatment of serious grampositive bacterial infections including those caused by methicillinresistant staphylococcus aureus mrsa with the continuous increase in bacterial resistance to currently marketed drugs serious infections are becoming more difficult if not impossible to treat and this has led to a clear need for novel therapeutics to treat multidrug resistant bacterial infections trius is headquartered in san diego california we have built a strong management team with significant development and regulatory experience our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of antiinfective drugs director    peninsula pharmaceuticals inc peninsula pharmaceuticals inc used to develop and commercialize antibiotics to treat life threatening infections the company used to develop optimal antiinfective therapies that offer improved efficacy dosing and safety characteristics over existing therapies it was founded in  the company was located in alameda ca director prior intekrin therapeutics inc intekrin therapeutics inc develops and commercializes therapeutics for metabolic and immune disorders it develops therapeutics for diabetes insulin resistance and multiple sclerosis the company was founded by dennis m lanfear and christos s mantzoros in  and is headquartered in palo alto ca director prior eiger biopharmaceuticals inc inactive eiger biopharmaceuticals inc provides pharmaceutical products it operates as a biopharmaceutical company which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis the firm’s pipeline includes clinical stage assets and preclinical new chemical entities nces shown to possess antiviral activity against hepatitis c hepatitis d and a wide array of other viruses it also conducts multiple clinical proofs of concept studies in multiple clinical sites in hcv and hdv patients the company was founded by jeffrey s glenn in  and is headquartered in palo alto ca independent director prior protagonist therapeutics inc protagonist therapeutics inc is a clinicalstage biopharmaceutical company which offers proprietary peptide technology platform which discovers and develops new chemical entities to address significant unmet medical needs the firms initial lead product candidates ptg and ptg is being developed for moderatetosevere ulcerative colitis and crohns disease respectively the company was founded by mark l smythe on august   and is headquartered in milpitas ca investments details hidden anthera pharmaceuticals inc anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca public holdings restricted data only for relsci professional users start my free trial ➤ see more transactions details hidden milestone pharmaceuticals inc raised money in a private placement transaction other affiliations paul f truex is affiliated with anthera pharmaceuticals inc milestone pharmaceuticals inc peninsula pharmaceuticals inc vicuron pharmaceuticals inc eli lilly  company eiger biopharmaceuticals inc cymabay therapeutics inc milestone pharmaceuticals inc anthera pharmaceuticals inc waterloo pharmaceuticals inc trius therapeutics inc peninsula pharmaceuticals inc intekrin therapeutics inc eiger biopharmaceuticals inc inactive protagonist therapeutics inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤   cymabay announces the appointment of paul f truex and robert j weiland to its board of directors nasdaqcbay english français register sign in cymabay announces the appointment of paul f truex and robert j weiland to its board of directors march    et  source cymabay therapeutics inc newark calif march   globe newswire  cymabay therapeutics inc nasdaqcbay today announced the appointment of paul f truex and robert j weiland to the company’s board of directors effective april   i would like to welcome paul truex and bob weiland to our board both have deep strategic and operational experience having held senior leadership roles in both largecap pharmaceutical and development stage biotechnology companies” said harold van wart phd chief executive officer of cymabay “paul brings both business acumen and operational experience to the board he has a track record of providing leadership at small cap biopharmaceutical companies bob has a wealth of experience in business and commercialization strategy including an indepth knowledge of the lipid lowering market from his previous work at abbott laboratories as we continue to advance cymabay through the next stage in its product development objectives it is important we have highly qualified industry experts on our board who can provide guidance based on significant experience” paul truex is currently president and ceo of anthera pharmaceuticals he was responsible for negotiating anthera’s product licenses for both blisibimod the company’s antibaff peptibody program from amgen and recently sollpura™ an enzyme replacement product from eli lilly  company during his career mr truex has been involved with over  million in financings and over  billion in strategic inlicensing outlicensing and merger and acquisition transactions prior to founding anthera he was a founder director president  ceo of peninsula pharmaceuticals during that time he negotiated both of peninsula’s product agreements with shionogi  co ltd doribax® doripenem and takeda chemical industries teflaro® ceftaroline peninsula was sold to johnson  johnson for  million and the remaining entity cerexa was subsequently acquired for  million prior to peninsula mr truex was vp of commercial development of versicor incorporated acquired by pfizer where he directed early commercial efforts in infectious disease prior to joining versicor mr truex worked at eli lilly and company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market his business development experience includes the lilly icos llc joint venture for the development of cialis® and two product divestitures anidulafungin eraxis® and loracarbef lorabid® mr truex obtained a masters of business administration in marketing and finance from indiana university and a bachelor of arts degree in economics from the university of waterloo  robert j “bob” weiland is a seasoned commercial executive having held senior leadership roles in both largecap pharma and biotechnology companies most recently bob worked at baxter international where he served as vice president strategy for baxter international and where he led the reconstruction of baxter’s worldwide gotomarket strategy prior to that he was baxter international’s vice president corporate development where he was responsible for baxter’s global business development organization and shared leadership responsibilities for baxter’s  million venture fund bob initially joined baxter as its vice president strategy  portfolio planning for baxter’s bioscience business in this role he led strategy development including specialty therapeutics business development and strategic portfolio management for baxter’s  billion bioscience business which has since been spun off as an independent biotechnology company baxalta prior to baxter mr weiland was vp of operations and strategic analytics for takeda pharmaceuticals north america before takeda he headed the clinical commercial and operational activities for the surgery business unit of the medicines company as its vice president and general manager prior to that he served for more than  years in a variety of senior domestic and international marketing general management and business development roles at abbott laboratories including the inlicensing launch and subsequent building of tricor the foundation of abbott’s lipidlowering franchise mr weiland earned a bachelor of science degree from desales university center valley pennsylvania and a masters in business administration in finance and marketing from the wharton school at the university of pennsylvania about cymabay cymabay therapeutics inc cbay is a clinicalstage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need including serious rare and orphan disorders cymabay’s product candidate mbx is a potent selective orally active pparδ agonist a phase  study of mbx in patients with mixed dyslipidemia established that it has an antiatherogenic lipid profile cymabay has completed a pilot phase  study of mbx in patients with homozygous familial hypercholesterolemia and has an ongoing phase  study in patients with primary biliary cholangitis arhalofenate cymabay’s other product candidate is a potential uratelowering antiflare therapy that has completed five phase  studies in gout patients arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney this dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia for additional information about cymabay visit wwwcymabaycomcontacts sujal shah cymabay therapeutics inc   sshahcymabaycom or hans vitzthum lifesci advisors llc  hanslifesciadvisorscom related articles other press releases by cymabay therapeutics inc cymabay announces pricing of public offering of common stock july    cymabay announces proposed public offering of common stock july    cymabay announces positive interim results from its ongoing lowdose phase  study of seladelpar in patients with primary biliary cholangitis july    cymabay announces the appointment of klara dickinson as senior vice president regulatory affairs and quality assurance and the promotion of daniel menold to vice president finance june    cymabay reports first quarter  financial results and provides corporate update may     other news releases in directors and officers in the last  days profile cymabay therapeutics inc   subscribe via rss  subscribe via atom  javascript newark california united states contact data contacts sujal shah cymabay therapeutics inc   sshahcymabaycom or hans vitzthum lifesci advisors llc  hanslifesciadvisorscom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files cymabay therapeutics inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved anth paul f truex insider trades for anthera pharmaceuticals inc bulletin investor alert london markets close in currencies futures metals stocks expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close anthera pharmaceuticals inc nasdaq anth go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus anthera pharmaceuticals inc market open  real time quotes jul    am anth quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual paul f truex mr paul f truex is chairman at milestone pharmaceuticals inc and chief executive officer  director at anthera pharmaceuticals inc he is on the board of directors at cymabay therapeutics inc anthera pharmaceuticals inc and waterloo pharmaceuticals inc mr truex was previously employed as independent director by trius therapeutics inc president chief executive officer  director by peninsula pharmaceuticals inc a principal by eli lilly  co and independent director by protagonist therapeutics inc he also served on the board at eiger biopharmaceuticals inc old and intekrin therapeutics inc he received his undergraduate degree from the university of waterloo and an mba from indiana university transactions date shares transaction value     gift at  per share      gift at  per share      derivativenonderivative trans at  per share      gift at  per share                award at  per share      gift at  per share      gift at  per share           gift at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      derivativenonderivative trans at  per share      award at  per share      gift at  per share      award at  per share      gift at  per share      gift at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr paul f truex executive chairman mr john craig thompson president chief executive officer  director ms may liu cao senior vpfinance  administration dr william r shanahan chief medical officer dr renee martin senior vice presidentmedical science dr christopher s henney director mr brent furse director mr nikhil agarwal headinvestor relations mr bradley a bugdanowitz secretary mr david e thompson independent director dr philip t sager independent director mr brian r mueller independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aubs downgrades goldman on limited confidence for revenue growth adow sp  slide as telecom utilities shares retreat aexistinghome sales fall in june as prices soar to fresh record aboeing stock price target raised to  from  at canaccord genuity amidcon energy partners stock price target cut to  from  at ubs alegacy reserves stock price target cut to  from  at ubs atractor supply stock price target cut to  from  at ubs aschlumberger stock price target cut to  from  at ubs atravelers stock price target raised to  from  at ubs aus stock market could get powerful tailwind from weaker dollar morgan stanley akansas city southern stock price target raised to  from  at ubs aironwood pharmaceuticals stock price target raised to  from  at ubs aathenahealth stock price target raised to  from  at ubs aabbott laboratories stock price target raised to  from  at ubs ainvesting according to your values can also make you money ahere’s how wealthy americans keep the best for themselves aa yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ agoldman sachs stock drops  after analyst downgrade agoldman sachs stock price target cut to  from  at ubs agoldman sachs downgraded to neutral from buy at ubs loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  paul truex  anthera pharmaceuticals inc  zoominfocom